Breaking: Carvana Boosts Outlook; Bullish View On RAPT Therapeutics
- August 09th, 2023
- 289 views
Shares of Carvana Co. (NYSE: CVNA) surged over 5% in pre-market trading following its announcement of an enhanced Q3 2023 outlook. The improvement is attributed to significant advancements in key business drivers and strong early-quarter momentum.
Specifically, Carvana has raised its Q3 adjusted EBITDA view to exceed $75 million, marking a shift from positive adjusted EBITDA.
$CVNA was trading at $47.50 in pre-market, reflecting a substantial increase of $3.49 (+7.93%).
In other news, RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company, received positive attention from Stifel as the investment banking firm initiated coverage with a Buy rating and a price target of $40.
Closing at $22.58 on Tuesday, this suggests a potential upside of $17.42 or approximately 77.03% for $RAPT, according to Stifel's assessment.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Micron Technology, Jabil, and Birkenstock Earnings Preview: What to Expect
December 15th, 2024Upcoming Earnings: Synopsys, AeroVironment, and nCino in Focus
December 01st, 2024Countdown to Earnings: Salesforce, Marvell Technology, and Okta Take the Stage
December 01st, 2024Fluence Energy, Agilent Technologies, and Woodward Earnings On Deck: A Preview
November 24th, 2024Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024
Member Login